Microablative fractional CO2-laser therapy and the genitourinary syndrome of menopause: An observational study. (December 2016)

• Record Type: Journal Article
• Authors: Pitsouni, Eleni; Grigoriadis, Themos; Tsiveleka, Angeliki; Zacharakis, Dimitris; Salvatore, Stefano; Athanasiou, Stavros
• Is Part Of: Maturitas. Volume 94(2016)
• Page Start: 131
• Page End: 136
• Publication Date: 2016-12
• Subjects: Menopause -- Urinary incontinence -- Urgency -- Sexual function -- Dyspareunia -- Vulvovaginal atrophy; Climacteric -- Periodicals; Menopause -- Periodicals; Climacteric -- Periodicals; Geriatrics -- Periodicals; Menopause -- Periodicals; Middle Aged -- Periodicals; Climatère -- Périodiques; Ménopause -- Périodiques; Climacterium; Climacteric; Menopause; Electronic journals; Periodicals; 612.66
• DOI: 10.1016/j.maturitas.2016.09.012
• Languages: English
• ISSNs: 0378-5122

Abstract

Highlights: The genitourinary syndrome of menopause involves clinical signs and symptoms in both the genitals and the lower urinary tract. In our study, Vaginal Maturation Value and Vaginal Health Index Score showed signs of improvement after CO2 -laser therapy. Indications of alleviation of symptoms in the genitals and lower urinary tract were noted. CO2 -laser therapy might be beneficial for the female sexual function and quality of life. Abstract: Objectives: This study aimed to assess the effect of the Microablative Fractional CO2 Laser (CO2 -laser) therapy on vaginal pathophysiology and the symptoms of the Genitourinary Syndrome of Menopause (GSM). Methods: Postmenopausal women with moderate to severe symptoms of GSM underwent three sessions of CO2 -laser therapy at monthly intervals. Participants were evaluated at baseline and 4 weeks after the last treatment. Main outcome measures: The primary outcomes were Vaginal Maturation Value (VMV) and Vaginal Health Index Score (VHIS). Secondary outcomes included symptoms of GSM, Female Sexual Function Index (FSFI), International Consultation on Incontinence Questionnaire of Female Urinary Tract Symptoms (ICIQ-FLUTS) and Urinary Incontinence Short Form (ICIQ-UI SF), Urogenital Distress Inventory (UDI-6) and King's Health Questionnaire (KHQ). Results: Fifty-three postmenopausal women completed this study. VMV, VHIS and FSFI increased significantly. Dyspareunia, dryness, burning, itching, dysuria, frequency, urgency, urgency incontinence, stress incontinence and scores on the ICIQ-FLUTS, ICIQ-UI SF, UDI-6 and KHQ decreased significantly. Factors predicting for which women the CO2 -laser therapy was more effective were not identified. Conclusion: This study suggests that intravaginal CO2 -laser therapy for postmenopausal women with clinical signs and symptoms of GSM may be effective in improving both vaginal pathophysiology and reported symptoms.